Brett C. Urig

Associate
Orange County
  • 650 Town Center Drive
  • 20th Floor
  • Costa Mesa, CA 92626-1925
  • USA
Profile Experience

Brett Urig is an associate in the Orange County office. 

Mr. Urig has a broad-based transactional practice, with a focus on advising clients in connection with mergers and acquisitions, carve-outs, exits, complex investments, securities compliance, and corporate governance matters.   

Mr. Urig’s practice spans a variety of sectors ranging from life sciences and healthcare to technology, real estate, and gaming.  

While in law school, Mr. Urig was a member of the Editorial Board for the Virginia Sports & Entertainment Law Journal, as well as a participant in the Criminal Defense Clinic. 

Mr. Urig’s representative transactions include advising public and private companies in the following matters: 
Mergers & Acquisitions

Life sciences and healthcare transactions

  • Acquisition of genetic testing company
  • US$300 million sale of a medical device business unit to an international company
  • US$5.6 billion sale to a generic specialty pharmaceutical company
  • Acquisition of an international medical device company
  • Publicly traded biopharmaceutical company in its consideration of an unsolicited takeover attempt

Technology transactions

  • Public company in its US$43 million acquisition of data services company
  • Gaming company in its acquisition of a mobile gaming company
  • Medical technology company in its US$220 million sale to a publicly traded healthcare compan

Private equity and growth equity transactions

  • Private equity firm in its acquisition of a financial technology company 
  • Private equity firm in its acquisition of a food services company
  • Technology company in its sale of a majority stake to a private equity firm 
  • Private entertainment and media company in its sale to a private equity firm 
  • Private sports company in its sale to a private equity firm
Capital Markets
  • The underwriters in the IPO of common stock of a food technology company 
  • The underwriters in a US$4 billion offering of investment-grade notes by a biopharmaceutical company 
  • The underwriters in the IPO of common stock of a biopharmaceutical company 
  • Public REIT in its offering of US$143 million offering of convertible senior notes 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.